Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jan 2018
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 29 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 29 Dec 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 12 Dec 2017 Updates safety and efficacy results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology